aQIV
Biological
Seqirus USA Inc
Total Payments
$15,217
Transactions
131
Doctors
1
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $15,217 | 131 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $15,217 | 131 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Clinical Study to Evaluate the Safety Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children | Seqirus USA Inc | $8,417 | 1 |
| A Phase III Randomized Observer-Blind Controlled Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults greater than or equal to 65 Years of Age | Seqirus USA Inc | $6,800 | 0 |
Top Doctors Receiving Payments for aQIV
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $14,917 | 130 |
| , M.D | Anatomic Pathology & Clinical Pathology | Tucson, AZ | $300.00 | 1 |
Ad
Manufacturing Companies
- Seqirus USA Inc $15,217
Product Information
- Type Biological
- Total Payments $15,217
- Total Doctors 1
- Transactions 131
About aQIV
aQIV is a biological associated with $15,217 in payments to 1 healthcare providers, recorded across 131 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2017. In 2017, $15,217 was paid across 131 transactions to 1 doctors.
The most common payment nature for aQIV is "Unspecified" ($15,217, 100.0% of total).
aQIV is associated with 2 research studies, including "Clinical Study to Evaluate the Safety Immunogenicity and Efficacy of Investigational Flu Vaccine Compared to Approved Flu Vaccine in Children" ($8,417).